Products
Nonacog Gamma Biosimilar Recombinant Protein (Factor IX) for Research
Pre-Made Nonacog Gamma Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Nonacog gamma is a new recombinant factor IX to treat factor IX deficiency. It is indicated for control of bleeding, perioperative management and routine prophylaxis to prevent or reduce the frequency of bleeding in adults and children with hemophilia B.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-929-1mg | 1mg | 3090 |
| GMP-Bios-INN-929-10mg | 10mg | |
| GMP-Bios-INN-929-100mg | 100mg | |
| GMP-Bios-INN-929-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Nonacog Gamma Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8 |
| INN Name | Nonacog Gamma |
| Target | F9 |
| Format | Recombinant Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | F9 (coagulation factor 9, coagulation factor IX) recombinant (variant_011773) glycosylated (glycoform alfa) |
| VD LC | F9 (coagulation factor 9, coagulation factor IX) recombinant (variant_011773) glycosylated (glycoform alfa) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Baxter BioScience (Westlake Village CA USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - F9
1. Protein Coagulation factor IX
2. Gene F9
3. Organism Homo sapiens (Human)
Function
Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca2+ ions, phospholipids, and factor VIIIa.
Miscellaneous
In 1952, one of the earliest researchers of the disease, Dr. R.G. Macfarlane used the patient's surname, Christmas, to refer to the disease and also to refer to the clotting factor which he called the 'Christmas Factor' At the time Stephen Christmas was a 5-year-old boy. He died in 1993 at the age of 46 from acquired immunodeficiency syndrome contracted through treatment with blood products.
Catalytic activity
Selective cleavage of Arg-|-Ile bond in factor X to form factor Xa.
